Maven Clinic Launches Nationwide Direct-to-Consumer Platform for Integrated Women's Health

Event summary

  • Maven Clinic launched a direct-to-consumer platform on May 20, 2026, integrating GLP-1 and hormonal care with comprehensive women's health services across 30+ specialties.
  • New research from Maven found that 37% of women reported limited or nonexistent follow-up care after receiving GLP-1 or hormone medications.
  • The platform aims to address the gap between prescription and ongoing support, with 47% of women surveyed saying a single provider understanding their whole health would improve care.
  • Maven has raised over $425 million from leading healthcare and technology investors.

The big picture

Maven Clinic's expansion into direct-to-consumer services marks a strategic shift to capture a broader market beyond its existing employer and health plan partnerships. The move comes amid growing demand for integrated women's health solutions, particularly in the areas of GLP-1 and hormonal therapies, where current systems often fall short in providing comprehensive follow-up care. With over $425 million in funding and a decade of experience in virtual women's health, Maven is positioning itself to lead in a fragmented market.

What we're watching

Market Adoption
How Maven's direct-to-consumer model will compete with existing employer and health plan partnerships.
Clinical Integration
Whether Maven can sustain its integrated care model as the healthcare system increasingly consumerizes.
Regulatory Compliance
The pace at which regulatory frameworks will adapt to the integration of GLP-1 and hormonal care in virtual clinics.